Evidence map›Paper›PMID 41644606›Full record

ArticleScientific reports2026

Conditional survival after radiofrequency ablation for early-stage hepatocellular carcinoma.

Yi-Hao Yen, Sin-Hua Moi, Kwong-Ming Kee, Chao-Hung Hung, Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Chih-Yun Lin, Sheng-Nan Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Predictors of True Early Recurrence in Patients Undergoing Radiofrequency Ablation for Hepatocellular Carcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  2. Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas.Canadian journal of gastroenterology & hepatology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Hao YenDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan. cassellyen@yahoo.com.tw.
Sin-Hua MoiGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kwong-Ming KeeDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Chao-Hung HungDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Chien-Hung ChenDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Tsung-Hui HuDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Jing-Houng WangDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Chih-Yun LinBiostatistics Center of Kaohsiung Chang, Gung Memorial Hospital, Kaohsiung, Taiwan.
Sheng-Nan LuDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.

Funding

Kaohsiung Chang Gung Memorial Hospital CMRPG8N1131
6 · The paper itself

Abstract

We analyzed how conditional survival (CS) after radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC) predicts survival estimates over time. We enrolled 791 patients with newly diagnosed early-stage HCC (i.e., within Milan criteria) and Child-Pugh class A liver disease undergoing RFA. Three-year CS, calculated as CS = S(x + 3)/S(x), was the probability of surviving an additional three years, given that the patient had already survived x years. One-, three-, and five-year overall survival rates were 96.3, 72.3, and 59.7%, respectively, and were lower for patients with a MELD score of > 9, BCLC stage A disease, and AFP level of ≥ 20 ng/ml. However, three-year CS showed that patients ablated for BCLC stage A or AFP ≥ 20 ng/ml had the same survival probabilities as patients with BCLC stage 0 or AFP < 20 ng/ml from the third year onward after RFA. In contrast, the three-year CS of patients with a MELD score of ≤ 9 was always better than that of patients with a MELD score of > 9. We concluded that CS showed that the impact of different variables on survival after RFA is not linear over time. Information derived from CS can be used to dynamically predict the prognosis of patients with HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRadiofrequency AblationAgedCatheter AblationFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisSurvival RateTreatment OutcomeConditional survivalHepatocellular carcinomaRadiofrequency ablation

Identifiers

PMID41644606
PMCPMC12929681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.